Evidence map›Paper›PMID 42653505›Full record

ReviewInternational journal of molecular sciences2026

Glutathione Biology in Neurodegenerative and Metabolic Diseases: Molecular Mechanisms, Pathophysiological Roles, and Therapeutic Perspectives.

Grażyna Gromadzka, Magdalena Kąkol, Magdalena Klimkiewicz, Maria Bendykowska

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grażyna GromadzkaDepartment of Biomedical Sciences, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Wóycickiego Street 1/3, 01-938 Warsaw, Poland.ORCID 0000-0002-4325-8971
Magdalena KąkolStudent Scientific Society "Immunis", Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Wóycickiego Street 1/3, 01-938 Warsaw, Poland.
Magdalena KlimkiewiczStudent Scientific Society "Immunis", Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Wóycickiego Street 1/3, 01-938 Warsaw, Poland.
Maria BendykowskaMilitary Institute of Medicine, National Research Institute, Szaserów Street 128, 04-141 Warsaw, Poland.ORCID 0009-0000-4900-9549

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutathione is an abundant intracellular low-molecular-weight thiol that contributes importantly to cellular redox homeostasis. Besides its well-established role in the antioxidant defense of the cell, glutathione regulates mitochondrial function, metabolism of toxicants, protein thiol oxidation/reduction, redox signaling, and immunity. Disturbances in glutathione metabolism have been shown to play a role in various diseases; however, it has become clear that changes in glutathione metabolism are a part of a complex, multifactorial process. In this review, we summarize current knowledge of the molecular mechanisms governing glutathione synthesis, recycling, compartmentalization, and biological functions, with particular emphasis on redox signaling, the nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (Nrf2/Keap1) pathway, and reversible protein S-glutathionylation. We further examine how disturbances in glutathione homeostasis interact with mitochondrial dysfunction, chronic inflammation, metabolic stress, and impaired cellular signaling in Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, Wilson's disease, type 2 diabetes, and nonalcoholic fatty liver disease. We also evaluate current translational interventions targeting restoration of glutathione balance through glutathione supplementation, precursor supplementation, pharmacological modulation of endogenous antioxidant mechanisms, dietary interventions, and changes in lifestyle. Despite the fact that many interventions have been promising at the mechanistic and experimental level, there are still insufficient clinical data because of the problems associated with glutathione availability, tissue specificity, disease variability, and a lack of sufficiently powered clinical trials. The conclusion of this review is that glutathione should not be viewed as a universal therapeutic target; instead, glutathione should be perceived as an important factor contributing to cellular resilience and able to help other disease-specific interventions. Future progress in glutathione-based interventions will likely depend on integrating redox biomarkers, patient stratification, and precision medicine strategies to identify individuals most likely to benefit from targeted modulation of glutathione homeostasis.

Indexed as

GlutathioneMetabolic DiseasesNeurodegenerative DiseasesAnimalsAntioxidantsHomeostasisHumansKelch-Like ECH-Associated Protein 1MitochondriaNF-E2-Related Factor 2Oxidation-ReductionOxidative StressSignal TransductionAntioxidantsGlutathioneKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2antioxidant therapyglutathionemetabolic diseasesmitochondrial glutathioneneurodegenerative diseasesNrf2oxidative stressredox homeostasisS-glutathionylation

Identifiers

PMID42653505
PMCPMC13513660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.